UConn STEP-HI — Testosterone Gel Blocks Visceral Fat in 65+ Women. Exercise Alone Can't
BODY

UConn STEP-HI — Testosterone Gel Blocks Visceral Fat in 65+ Women. Exercise Alone Can't

By Polly · · Obesity Pillars 2026 / UConn STEP-HI
KO | EN

First clinical evidence that exercise alone can’t block visceral fat. Obesity Pillars 2026 (UConn STEP-HI trial, ScienceDaily 2026.5.7 coverage) — 66 women aged 65+ in hip fracture recovery, 6-month follow-up. Testosterone gel + exercise group: visceral fat decreased / Exercise alone group: visceral fat normally increased. Lead researcher Jacob Earp (UConn kinesiology). Dangerous visceral fat naturally accumulating in abdomen post-menopause — exercise alone can’t stop it. First RCT data showing hormone axis must be addressed together.

Meaning of Visceral Fat

Visceral Adipose Tissue (VAT):

  • Fat accumulating around abdominal organs
  • Different circuit from subcutaneous fat
  • Secretes chronic inflammatory cytokines (IL-6·TNF-α·leptin)
  • ↑↑ insulin resistance + cardiovascular risk + diabetes + Alzheimer’s risk

Female visceral fat shift:

  • Premenopausal: subcutaneous fat dominant (hips·thighs)
  • Postmenopausal: ↑↑ visceral fat (abdomen)
  • Rapid increase within 1~3 years
  • Hard to recover with exercise·diet alone

Causes:

  • ↓ estrogen → fat distribution shift
  • ↓ testosterone → ↓ muscle mass + ↑ fat
  • Insulin resistance → abdominal fat accumulation
  • ↑ cortisol (chronic stress) → abdominal fat

Limits of Existing Recommendations

Existing standards:

  • Diet (Mediterranean·low-calorie)
  • Exercise (aerobic + resistance)
  • Weight loss
  • Simple “healthy lifestyle”

Outcome gap:

  • Same exercise·diet sees ↑ visceral fat in postmenopausal women
  • “Why does my belly grow despite same exercise?”
  • Hormone axis influence ignored

STEP-HI Trial Design

STEP-HI (Strategies to Enhance the Pelvic and Hip Femoral Integrity):

  • Lead: Jacob Earp (UConn kinesiology)
  • Journal: Obesity Pillars (2026; 17:100247)

Study design:

  • 66 women aged 65+
  • Hip fracture recovery (rehabilitation period)
  • 6-month follow-up
  • Randomized:
    • Testosterone gel + exercise vs
    • Placebo gel + exercise

Measurements:

  • Visceral fat (DXA·CT)
  • Subcutaneous fat
  • Muscle mass
  • Muscle strength
  • Safety (liver enzymes·cardiovascular·acne·hirsutism)

Key Results

1. Visceral fat change:

  • Testosterone gel + exercise: visceral fat decreased
  • Placebo gel + exercise: visceral fat normally increased (despite rehabilitation exercise)

2. Subcutaneous fat·muscle:

  • Both groups recovered muscle (exercise effect)
  • Testosterone group slightly better muscle preservation

3. Safety:

  • Zero side effects in 6 months (low-dose titration)
  • No liver enzyme·acne·hirsutism changes

Clinical significance:

  • First quantified data showing “exercise + diet alone insufficient”
  • Message that hormone axis must be addressed
  • Possibility of new indication for testosterone in postmenopausal women

Two Tracks of Female Testosterone (L63·L67·L69)

Female testosterone cluster:

1. HSDD (low libido):

  • L63·L67 transdermal testosterone
  • Medherant TEPI patch (phase 1~2)
  • First formal FDA indication filing in progress

2. Visceral fat (L69 new):

  • UConn STEP-HI 65+ women
  • Integrated with rehabilitation exercise
  • Possible future indication

3. Bone density:

  • Postmenopausal osteoporosis adjunct
  • Some clinics off-label

General Application Guidelines — Cautiously

STEP-HI result limitations:

  • Limited to 65+ women in hip fracture recovery
  • Separate RCT needed for general postmenopausal women
  • 6-month short-term data

Currently NOT recommended:

  • Testosterone for all postmenopausal women
  • Self-prescription
  • Informal clinic prescriptions

Future possibilities:

  • Integration with L63·L67 HSDD indication
  • Precision hormone matrix (estrogen + progesterone + testosterone)
  • Physician·OBGYN·endocrinology integrated decision

Natural Matrix — Postmenopausal Visceral Fat Reduction

Diet:

  • Protein 1.2~1.6 g/kg/day (muscle preservation)
  • Fiber 25~35 g/day
  • ↓ processed food·sugar
  • Anti-inflammatory diet (Mediterranean·MIND)
  • ↓ alcohol

Exercise:

  • Resistance exercise 2~3x/week (muscle·bone density)
  • Aerobic 150+ min/week (direct visceral fat effect)
  • HIIT adjunct

Sleep·stress:

  • 7~9 hours sleep
  • ↓ chronic stress (cortisol drives abdominal fat)
  • Meditation·breathwork (L68)

Measurements:

  • Waist circumference (>90cm men, >85cm women at risk)
  • BMI
  • DXA (precise body composition, medical institution)
  • L67 metabolome (cardiovascular risk integration)

Drug Matrix (Visceral Fat Options)

1. GLP-1 drugs (L65·L66):

  • Semaglutide (Wegovy)·tirzepatide (Mounjaro)
  • Visceral fat dominant reduction
  • Applicable to 30~50s too

2. Hormone replacement therapy (MHT):

  • Estrogen + progesterone
  • Some visceral fat normalization
  • OBGYN decision

3. Testosterone (experimental):

  • L69 STEP-HI data
  • Validated in 65+ fracture recovery
  • General application needs RCT

4. Metformin:

  • Insulin resistance patients
  • Some visceral fat reduction

Korean Clinical Significance

Korean postmenopausal women visceral fat:

  • Korean obesity diagnosis criteria (waist >90cm men, >85cm women)
  • Rapid postmenopausal increase
  • ↑ cardiovascular·diabetes risk

Korean medical options:

  • L65·L66 GLP-1 non-reimbursed (₩300,000~700,000/month)
  • MHT partial insurance
  • Female testosterone indication: not Korean MFDS approved, only off-label

Conclusion

UConn STEP-HI is first RCT evidence integrating hormone axis for postmenopausal female visceral fat. Exercise alone insufficient; testosterone + exercise synergy. With L63·L67 HSDD testosterone track + L65·L66 GLP-1 + L68 APOE4·30-pillar matrix, L69 adds visceral fat track. Postmenopausal women’s precision medicine integrates hormone·muscle·fat·cardiovascular·brain into one matrix. General application after RCT, meanwhile precision decision via natural·drug matrix is standard.

Source: Obesity Pillars 2026 / UConn STEP-HI